Orencia Package Insert

HIGHLIGHTS OF PRESCRIBING INFORMATION Known Hypersensitivity ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INVANZ safely and effectively. See full prescribing information for INVANZ. INVANZ®(ertapenemfor injection) for intravenous (IV) or intramuscular (IM) use Initial U.S. Approval: 2001 ... Get Content Here

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab ...
REMICADE® (Rem-eh-kaid) (infliximab) Lyophilized Concentrate for Injection, for Intravenous Use ORENCIA (abatacept), ACTEMRA (tocilizumab), or other medicines called biologics that are used to treat the same conditions as REMICADE. ... Document Viewer

ORENCIA® (abatacept) - AZBlue
1. Orencia Package Insert. FDA-approved indication and dosage: Indication Recommended Dose Adult moderately to severely active rheumatoid arthritis Intravenous: Following the initial dose, give at 2 and 4 weeks, then every 4 weeks Body weight less than 60kg: 500mg Body weight 60 to 100 kg 750mg More than 100kg 1000mg ... Access Doc

HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
See full prescribing information for complete boxed warning. Hepatitis B virus(HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death. ... Fetch Document

HIGHLIGHTS OF PRESCRIBING INFORMATION Hypocalcemia May Worsen ...
FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Treatment of Osteoporosis in Postmenopausal Women 1.2 Prevention of Osteoporosis in Postmenopausal Women 1.3 Osteoporosis in Men 1.4 Glucocorticoid-Induced Osteoporosis 1.5 Paget's Disease of Bone 1.6 Important Limitations of Use 2 DOSAGE AND ADMINISTRATION ... Fetch Doc

SPECIALTY GUIDELINE MANAGEMENT - Caremark
Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2015. 2. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. ... Fetch This Document

1. Cimzia [package insert]. Smyrna, GA: UCB, Inc.; April 2016. 2. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. ... View Document

ORENCIA (abatacept) - Caremark
ORENCIA (abatacept) RATIONALE FOR INCLUSION IN PA PROGRAM . Background . Orencia is a prescription medication that reduces signs and symptoms in adults with moderate to Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2017. ... Fetch Full Source

HIGHLIGHTS OF PRESCRIBING INFORMATION CONTRAINDICATIONS These ...
Ozurdex (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). ... Get Content Here

SPECIALTY GUIDELINE MANAGEMENT - Nhp.org
Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2017. 2. Smolen JS, Landewé R, Billsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. ... Get Doc

Approval Criteria Department Of Pharmacy Services
Orencia (abatacept) lyophilized powder for intravenous infusion [package insert]. Bristol-Myers Squibb Company; 2009. 13. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of ... Document Retrieval

Orencia® (abatacept) - Moda Health
Orencia 250 mg single-use vial: 00003-2187-xx Orencia ClickJect 125 mg/mL Autoinjector and prefilled syringe: 00003-2188-xx Orencia prefilled syringe 50 mg/0.4 mL: 00003-2814-xx Orencia prefilled syringe 87.5 mg/0.7 mL: 00003-2818-xx VII. References 1. Orencia [package insert]. Princeton, NJ; Bristol-Myers Squibb; June 2017. ... Document Retrieval

Pharmacy Medical Necessity Guidelines: Orencia (abatacept)
Orencia (abatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2017. 12. Ruperto N, Lovell DJ, Quartier P et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. ... Access Document

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for TALTZ. TALTZ (ixekizumab) injection, for subcutaneous use Initial U.S. Approval: 2016 ... Retrieve Content

Nucala PI-PIL - GSKSource
History of hypersensitivity to mepolizumab or excipients in the formulation. (4) ----- WARNINGS AND PRECAUTIONS ----- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. ... Get Content Here

Effective Date: 11/09/2017 - Bcbsm.com
1. Orencia® [package insert] Princeton, NJ: Bristol,-Myers Squibb; June 2017 2. Singh et al. 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. 2012, ... Fetch This Document

PHARMACY POLICY STATEMENT - CareSource
PHARMACY POLICY STATEMENT Ohio Medicaid DRUG NAME Orencia (abatacept) BILLING CODE J0129 (1 unit = 10 mg)—infused product Must have valid NDC for self-administered product Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; March, 2017. 2. American College of ... Get Content Here

SIMPONI ARIA Med Guide Cp-60629v1 - Janssenlabels.com
You should not receive SIMPONI ARIA while you are also receiving ORENCIA (abatacept) or KINERET (anakinra). • use other TNF-blocker medicines, including REMICADE (infliximab), HUMIRA (adalimumab), ENBREL (etanercept), or CIMZIA ... Fetch Content